Our ddRNAi technology has the potential to treat a broad range of human diseases – including cancers, neurological diseases, infectious diseases, autoimmune diseases, genetic diseases and other conditions associated with expression of a small number of key genes. Several biotechnology companies have licensed Benitec’s ddRNAi technology for use in their own human therapeutic programs including HIV/AIDS, Huntington’s Disease, chronic neuropathic pain and retinitis pigmentosa.